Leading
Distributor of Quality Pharmaceuticals
Medyk Lek is a dynamically developing company in the European pharmaceutical distribution market. We have over 20 years of experience.
Our main partners are pharmaceutical wholesalers, hospitals, and drug manufacturers. We also closely cooperate with a group of over 100 pharmacies.
Our strategy is organic growth and constant scaling of operations. To achieve this, we have built a team that professionally handles the entire ordering process and responds to our Clients' needs.
Your satisfaction is our success. Check us out:
- our response to your inquiry within 24 hours
- openness to the needs and specifics of our partners' activities
- readiness to build business relationships in a win-win arrangement (it's not just about the price)
- utmost diligence in preparing commercial and transport documentation
- supervision of the transaction process from the moment of order placement to the moment of goods delivery.
Cooperation with pharmacies
We collaborate with pharmacies across Poland. We offer a wide range of products and ensure their constant availability. Our offer includes products from all pharmaceutical categories. To provide a broad selection, we work with reputable manufacturers and distributors from both domestic and foreign markets.
Collaboration with Hospitals & NZOZ
An important branch of ML's activity is sales to the hospital market. Sales are conducted based on tender agreements as well as in a non-tender procedure.
Cooperation with domestic and foreign wholesalers
Medyk Lek Panek specializes in the sale of medicinal products, dietary supplements, and medical devices in countries across Europe, Asia, and Africa. Every day, we take action to ensure our offerings are attractive in terms of product range and pricing. We seek interesting products and work on building their availability. We operate in accordance with the DPD Certificate.
Clinical Trial Support
At Medyk Lek, we fully understand that supplying medicinal products for clinical research poses challenges for pharmaceutical and biotechnology companies, involving significant financial risks as well as risks of delays and exposure.